This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Yi-Shuan Sheen, MD; Cheng-Hsiang Hsiao, MD; Chia-Yu Chu, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Gefitinib (Iressa; AstraZeneca, London, England) has been used in the treatment of non–small cell lung cancer (NSCLC).¹ The cutaneous toxic effects associated with epidermal growth factor receptor (EGFR) inhibitors are follicular eruption, paronychia, and xerosis.^2-4 Herein, we describe 3 patients with reticular erythematous eruptions on the lower extremities associated with gefitinib.

Report of Cases

Case 1

A 77-year-old man with NSCLC began treatment with gefitinib, 250 mg/d, in January 2005. Concurrent medications were terazosin hydrochloride, flavoxate hydrochloride, diltiazem hydrochloride, valsartan, and metformin hydrochloride since 2002. After 2 weeks of gefitinib treatment, follicular eruptions were noted, followed by xerosis and paronychia. Erythematous papules and erosions developed in a linear pattern on the lower extremities in December 2005 (Figure 1). Results of platelet counts and coagulation profiles were within normal limits. Skin biopsy specimens showed a subcorneal pustule with neutrophilic infiltration and epidermal atrophy. Mild perivascular . . . [Full Text of this Article]

Case 2

Case 3

Comment

AUTHOR INFORMATION